Impact of Sitagliptin on Markers of β-cell Function: A Meta-Analysis

Despite significant improvement in HOMA-β index and PI/IR from placebo, there does not seem to be a benefit of dipeptidyl peptidase-IV inhibitors over other agents with respect to β-cell function/activity. Long-term prevention of β-cell dysfunction cannot be ruled out.